New drug cocktail targets rare spleen cancer in early trial

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people newly diagnosed with a rare type of lymphoma that affects the spleen. The goal is to see how well the treatment shrinks or controls the cancer and to check for side effects. About 47 adults aged 18 to 80 who have not had prior treatment for this lymphoma will take part.